Amneal Pharmaceuticals, Inc. (AMRX) Earnings Call Transcript & Summary

We are very excited to announce this collaboration between Amneal and Metsera to make millions of [indiscernible] and oral solids for GLP-1 products.

This collaboration with Amneal is utterly unique and for us, incredibly exciting. I have never seen someone put together this kind of technical scale, quality and affordability commitment with really cutting-edge new medicines.

Amneal stellar quality track record over 280 prescription drugs in the market, we are a powerhouse in manufacturing. We are very, very excited on breaking the ground on our new facility. It's going to be high class, high quality state-of-the-art new technology, new plant.

I think it's [ 2.5 billion ] worldwide in label for these drugs and imagine we could treat half of that. It's about 1/3 of the world population would qualify for one of these drugs. We think healthy weight loss assisted by therapeutics like those in our pipeline can be an empowering experience and I think being able to partner globally and in a way that will scale with the demands of that market is really exciting.

We are the preferred partners of Metsera to supply these products in U.S. and Europe and also Amneal is very excited to get the licensing rights of these products to supply in emerging markets; India, Southeast Asia, Africa.

Amneal bring that capacity. I think we bring the ingenuity of designing the molecules and developing them and that's going to make a huge difference to patients.

We can effectively play our role to make the humanity better and that's what drives us.